|
Category:natural substances and extractives
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 130.50 °C. @ 760.00 mm Hg
|
| Soluble in: |
| | water, 48.37 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intraperitoneal-mouse LD50 43500 ug/kg
Strahlentherapie. Vol. 127, Pg. 245, 1965.
intravenous-mouse LD50 6300 ug/kg
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 103, Pg. 146, 1955.
intravenous-rabbit LDLo 10 mg/kg
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Journal of Pharmacology and Experimental Therapeutics. Vol. 31, Pg. 43, 1927.
|
| Dermal Toxicity: |
subcutaneous-mouse LDLo 100 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 132, Pg. 63, 1928.
subcutaneous-rabbit LD50 35 mg/kg
Farmakologiya i Toksikologiya Vol. 4(1), Pg. 34, 1941.
subcutaneous-rat LDLo 80 mg/kg
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 132, Pg. 63, 1928.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | natural substances and extractives |
| Recommendation for (-)-lobeline usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for (-)-lobeline flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | 2-[(2R,6S)-6-[(2R)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 688025 |
| Pubchem (sid): | 134971117 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 8,10- | diphenyl lobelionol | | 8,10- | diphenyllobelionol | | | ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))- | | (2R-(2alpha,6alpha(S*)))-2-(6-(2- | hydroxy-2-phenyl ethyl)-1-methyl-2-piperidinyl)-1-phenyl ethanone | | 2-(6-(2- | hydroxy-2-phenyl ethyl)-1-methyl-2-piperidinyl)-1-phenyl ethanone | | 2-[(2R,6S)-6-[(2R)-2- | hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone | | 2-(6-(beta- | hydroxy-phenethyl)-1-methyl-2-piperidyl) acetophenone | | | inflatine | | | lobelina | | | lobeline | | | lobelinum |
Articles:
| PubMed:Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. |
| PubMed:Piperidine, pyridine alkaloid inhibition of fetal movement in a day 40 pregnant goat model. |
| PubMed:High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin binding. |
| PubMed:Surface plasmon resonance based biosensors for exploring the influence of alkaloids on aggregation of amyloid-β peptide. |
| PubMed:The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. |
| PubMed:meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. |
| PubMed:Consumption of bitter alkaloids in Drosophila melanogaster in multiple-choice test conditions. |
| PubMed:Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. |
| PubMed:The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. |
| PubMed:Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. |
| PubMed:Association constants of pyridine and piperidine alkaloids to amyloid beta peptide determined by electrochemical impedance spectroscopy. |
| PubMed:Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice. |
| PubMed:Interaction of lobeline and nicotinic receptor ligands with the discriminative stimulus properties of cocaine and amphetamine. |
| PubMed:Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. |
| PubMed:Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. |
|
an alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. it has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation.
|
3D/inchi